Loading
Life sciences · Journal article
Discover Oncology · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Breast cancer (BC) in young women is associated with more aggressive tumor biology, increased risk of recurrence, as well as worse prognosis, with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) subtype accounting for 54–61% of cases. While cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have become the standard treatment in both HR+/HER2- advanced BC (ABC) and early BC (EBC), their application in young BC (YBC) poses distinct challenges. Unlike postmenopausal patients, YBC frequently face premenopausal endocrine milieu, fertility preservation concerns, treatment-induced ovarian dysfunction, and long-term psychosocial burdens. In the adjuvant setting, key unanswered questions include whether adjuvant CDK4/6i can replace chemotherapy (CT) in intermediate-risk disease, how to sequence CDK4/6i with poly (ADP-ribose) polymerase inhibitors (PARPi) in breast cancer susceptibility gene ( BRCA )-mutated young patients, and how to time adjuvant therapy around fertility preservation. In the advanced setting, critical issues remain regarding the integration of CDK4/6i in BRCA or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA )-mutated patients, the timing of CDK4/6i initiation, the benefit of cross-line switching after progression, and whether CDK4/6i-based regimens can defer CT in visceral crisis. Moreover, patient-reported outcomes (PROs) and quality-of-life (QoL) data are critically lacking, which are essential for shared decision-making given the extended treatment trajectory. Future research must prioritize biomarker-driven strategies, head-to-head comparisons of CDK4/6i plus ovarian function suppression (OFS) versus CT, and integration of multidisciplinary team (MDT) care and PROs assessments. Addressing these unmet needs will be pivotal to advancing personalized, holistic management and improving long-term outcomes in YBC.